TXG | Ticker Profile - Titan Protect

TXG

10x Genomics, Inc.

Healthcare · Health Information Services · NMS

$31.04

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$3.2B

Total market value of the company

Trailing P/E

N/A

Forward P/E

127.55

Based on estimated future earnings — lower means cheaper

Rev Growth

-2.6%

Year-over-year revenue change

Profit Margin

-3.5%

How much profit the company keeps from each dollar of revenue

ROE

-3.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$25.00

-19% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 13 analysts covering this stock

About 10x Genomics, Inc.

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

https://www.10xgenomics.com

Country: United States Employees: 1,178 Industry: Health Information Services

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.527

Good returns relative to risk taken

Kelly Fraction

0.0262

Modest edge detected — smaller position warranted

Calmar Ratio

0.181

Drawdown risk outweighs the returns — higher risk profile

Annual Return

12.6%

Historical annualised return based on price data

Max Drawdown

-69.6%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

117

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.05

Significantly more volatile than the market

52W High

$26.45

-17% below the year high

52W Low

$8.81

252% above the year low

Avg Volume

2,535,575

Average daily shares traded — higher means easier to buy and sell

Short Ratio

8.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

25.9%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.17

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

10.00

Heavy leverage — higher financial risk if revenues decline

Current Ratio

5.90

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

5.25

Like current ratio but excludes inventory — stricter test

Gross Margin

69.7%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-11.3%

Profit from core operations before interest and tax

Free Cash Flow

$125M

Positive — the business generates more cash than it spends

Revenue (TTM)

$639M

Total revenue over the last 12 months

Net Income

$-22,656,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$32.00

Target Median

$25.00

Target Low

$20.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go